Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Michael L. Watkins"'
Autor:
François Maltais, Leif Bjermer, Edward M. Kerwin, Paul W. Jones, Michael L. Watkins, Lee Tombs, Ian P. Naya, Isabelle H. Boucot, David A. Lipson, Chris Compton, Mitra Vahdati-Bolouri, Claus F. Vogelmeier
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-15 (2019)
Abstract Background Prospective evidence is lacking regarding incremental benefits of long-acting dual- versus mono-bronchodilation in improving symptoms and preventing short-term disease worsening/treatment failure in low exacerbation risk patients
Externí odkaz:
https://doaj.org/article/4397ec211a684a41994894718e1f28f9
Autor:
Krishna Pudi, Charlotte Baidoo, Eric D. Bateman, Catriona Crawford, Courtney Crim, Shuyen Ho, Michael L. Watkins, Ramiro Castro-Santamaria, Isabelle Schenkenberger, Gregory Feldman, Edward Kerwin
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease. 14:615-629
Background Batefenterol is a novel bifunctional muscarinic antagonist β2-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose-response o
Autor:
Chris Compton, Claus Vogelmeier, Ian Naya, Paul W. Jones, Isabelle Boucot, Edward Kerwin, Lee Tombs, Michael L. Watkins, Mitra Vahdati-Bolouri, François Maltais, Leif Bjermer, David A. Lipson
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-15 (2019)
Respiratory Research
Respiratory Research
Background Prospective evidence is lacking regarding incremental benefits of long-acting dual- versus mono-bronchodilation in improving symptoms and preventing short-term disease worsening/treatment failure in low exacerbation risk patients with chro
Autor:
A. Compagnon, Isabelle Boucot, David A. Lipson, Michael L. Watkins, Leif Bjermer, L. Tombs, François Maltais, Chris Compton, Paul W. Jones, Ian Naya, Claus Vogelmeier, Edward Kerwin
Publikováno v:
Revue des Maladies Respiratoires Actualités. 12:189-190
Introduction Les bronchodilatateurs (BD) beta 2-agonistes de longue duree d’action (LABA) et/ou les anticholinergiques de longue duree d’action (LAMA) sont recommandes en traitement de 1re intention chez les patients atteints de BPCO. Leur associ
Autor:
David A. Lipson, François Maltais, Michael L. Watkins, Paul W. Jones, Ian Naya, Chris Compton, Leif Bjermer, Isabelle Boucot, Lee Tombs, Edward Kerwin
Publikováno v:
COPD: therapeutics and trials.
Introduction Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) combination therapy is more effective than monotherapies for improving lung function, breathlessness and health status, in patients with moderate-to-severe COPD (Oba e
Autor:
Harvey O. Coxson, Ruth Tal-Singer, Edwin K. Silverman, William MacNee, Stephan I. Rennard, Bartolome R. Celli, Erica P.A. Rutten, Richard Casaburi, Courtney Crim, Paul D. Scanlon, Alvar Agusti, Jørgen Vestbo, Michael L. Watkins, Emiel F.M. Wouters, Peter M.A. Calverley, Per Bakke, David A. Lomas, Bruce E. Miller
Publikováno v:
Annals of Nutrition and Metabolism, 63(3), 239-247. Karger
Aims: The follow-up of the ECLIPSE study, a prospective longitudinal study to identify and define parameters that predict disease progression over 3 years in chronic obstructive pulmonary disease (COPD), allows the examination of the effect of body c
Autor:
Bruce E. Miller, Michael L. Watkins, Marie-Kathrin Breyer, Erica P.A. Rutten, Emiel F.M. Wouters, Nicholas Locantore
Publikováno v:
European Journal of Clinical Investigation. 42:983-991
Eur J Clin Invest 2012; 42 (9): 983–991 Abstract Background Research concerning the involvement of body composition and systemic inflammatory markers in adipokine metabolism in chronic obstructive pulmonary disease (COPD) is still limited. Therefor
Autor:
Bartolome R. Celli, Alvar Agusti, David A. Lomas, Julie C. Yates, Ruth Tal-Singer, Harvey O. Coxson, Victor Pinto-Plata, Jørgen Vestbo, William MacNee, Michael L. Watkins, Michael I. Polkey, Courtney Crim, Stephen I. Rennard, Martijn A. Spruit, Edwin K. Silverman, Lisa D. Edwards, Peter M.A. Calverley, Emiel F.M. Wouters
Publikováno v:
Journal of the American Medical Directors Association, 13(3), 291-297. Elsevier Science
BACKGROUND: Exercise tolerance is an important clinical aspect of chronic obstructive pulmonary disease that can be easily and reliably measured with the 6-minute walking test (6MWT). To improve the utility of the 6MWT for patient and health care sys
Autor:
Lisa D. Edwards, Michael L. Watkins, Jørgen Vestbo, Ruth Tal-Singer, Peter M.A. Calverley, Bartolome R. Celli, Emiel F.M. Wouters, Victor Pinto-Plata, Martijn A. Spruit
Publikováno v:
Respiratory Medicine, 104(6), 849-857. Elsevier Saunders
BACKGROUND: The 6-min walking test (6MWT) is widely used to assess exercise tolerance in patients with chronic obstructive pulmonary disease (COPD). Given the prognostic significance of the 6MWT, it is important to identify why some COPD patients per
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Robust biomarkers for COPD may help direct patient-specific therapy, e.g. sputum eosinophilia in COPD patients predicts clinical response to ICS (Brightling C.E. et al. Thorax 2005:60:193-8). Peripheral blood eosinophil count has also been proposed a